Guska, Scaffold Biotech, and Eolo Pharma were selected among the ten stories honored in the 10th edition of the Nova Award, organized by Uruguay’s National Agency for Research and Innovation (ANII).
Over its previous nine editions, NOVA has recognized high-impact projects from startups, companies, public and private institutions, foundations, and schools. This year, the award chose to highlight ten initiatives as a tribute. The public will vote to decide who receives “La 10 de la innovación”—a symbolic distinction for the most-voted story.
The Nova Award highlights innovative initiatives with real impact and promotes a culture of innovation across different fields.
Scaffold Biotech and Guska are startups supported by LAB+ Company Builder. Scaffold Biotech is developing a vaccine against cattle ticks, while Guska is working on oncolytic viruses to target tumor cells.
Eolo Pharma -founded by researchers from the Institut Pasteur de Montevideo and the University of the Republic, and boosted by the General Partners of LAB+- is developing a drug for the prevention and treatment of obesity and its metabolic complications, such as type 2 diabetes.
More information about the award and voting is available here.
